Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Myelofibrosis
Pacritinib Therapy in a Patient With End-Stage Renal Disease in the Setting of Cytopenic Myelofibrosis
Alexandra Roach, MD; Hayley Heers, PharmD, BCPS, BCOP; Vishangi Dave, MD; Naveen Pemmaraju, MD; Matthew Ulrickson, MD
Read More
Managing and Mitigating Discontinuation Syndrome With Ruxolitinib and Other Novel JAK Inhibitors for Myelofibrosis
Justin Arnall, PharmD, BCOP; Joseph Elmes, PharmD, BCOP; Umesh Yogarajah, PharmD; Benson Meek, PharmD; Donald C. Moore, PharmD, BCPS, BCOP, DLPA, FCCP
Read More
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
Abstract #CT09
Read More
Meeting Highlights
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
Read More
Meeting Highlights
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis
Read More
Results 1 - 5 of 5
